SMV
CYTO

Sofinnova Management VIII’s Altamira Therapeutics Ltd CYTO Stock Holding History

Sofinnova Management VIII’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$4.62M Hold
98
– – 2.52% 6
2017
Q3 		$6.41M Hold
98
– – 3.91% 7
2017
Q2 		$5.63M Hold
98
– – 3.15% 6
2017
Q1 		$7.19M Buy
98
+25
+34% +$2.01M 3.79% 6
2016
Q4 		$6.22M Buy
+73
New +$7.24M 3.5% 5

Other funds holding CYTO

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sofinnova Management VIII's CYTO Position: Q4 2017 in Review

Sofinnova Management VIII held its Altamira Therapeutics Ltd (CYTO) position steady in Q4 2017 at 98 shares worth $4.62M. The position accounts for 2.52% of the portfolio, ranked #6.

Sofinnova Management VIII first reported a position in CYTO in Q4 2016 and has held it in 5 quarters since. The position peaked at $7.19M in Q1 2017. 8 funds tracked by Wall St. Rank hold CYTO as of Q4 2017.

  • Sofinnova Management VIII held 98 shares of Altamira Therapeutics Ltd worth $4.62M as of Q4 2017.
  • Sofinnova Management VIII left its Altamira Therapeutics Ltd share count unchanged in Q4 2017.
  • Altamira Therapeutics Ltd made up 2.52% of Sofinnova Management VIII's portfolio in Q4 2017, its #6 holding.
  • Sofinnova Management VIII first reported a position in Altamira Therapeutics Ltd in Q4 2016 and has held it in 5 quarters since.
  • Sofinnova Management VIII's Altamira Therapeutics Ltd position peaked at $7.19M in Q1 2017.
  • 8 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2017.

Based on Sofinnova Management VIII's 13F filing for Q4 2017, filed 14 Feb 2018.